Hans Burchardt
Frederiksberg Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Hans Burchardt.
European Heart Journal | 2003
Finn Gustafsson; Christian Torp-Pedersen; Bente Brendorp; Marie Seibæk; Hans Burchardt; Lars Køber
AIMS The purpose of this study was to evaluate the influence of left ventricular systolic function on the survival in a large consecutive cohort of patients hospitalized with congestive heart failure and to determine how left ventricular systolic function interacts with co-morbid conditions in terms of prognosis. METHODS AND RESULTS Analysis of survival data from 5491 patients admitted for new or worsening heart failure to 34 departments of cardiology or internal medicine in Denmark from 1993-1996 was carried out. A standardized echocardiogram was available for 95% of the patients, and left ventricular systolic function was estimated using wall motion index score. Follow-up time was 5-8 years. Patients with preserved systolic function were older, more frequently female, and had less evidence of ischemia than patients with systolic dysfunction. After 1 year, 24% of the patients had died. Low wall motion index was a potent independent predictor of death (risk ratio for one unit increase, 0.60 (0.56-0.64)), and was of greater prognostic significance in younger patients and patients with a history of myocardial ischemia. However, even in patients with preserved systolic function, mortality was high (1 year mortality, 19%). CONCLUSION In hospitalized heart failure patients, particularly in younger patients with ischemic heart disease, mortality risk is inversely related to left ventricular systolic function.
American Heart Journal | 1997
Marie Seibæk; Carsten Sloth; Lili Vallebo; Torben Hansen; Søren A. Urhammer; Hans Burchardt; Christian Torp-Pedersen; Oluf Pedersen; Per Hildebrandt
Increasing attention is being paid to disturbances in glucose metabolism as key explanatory factors for the development of coronary artery disease. We studied the prevalence of impaired glucose tolerance and non-insulin-dependent diabetes and the levels of plasma insulin after an oral glucose tolerance test in 99 men with heart disease but without a history of diabetes referred to coronary arteriography; we also compared the outcome with a matched control group (n = 116). The severity of atherosclerosis in coronary angiograms was evaluated according to glucose tolerance status. Among the 99 patients with coronary artery disease, 37.4% had an abnormal oral glucose tolerance test result, whereas only 18.1% of the control group had an abnormal result (p < 0.01). Moreover, patients with heart disease and normal glucose tolerance were hyperinsulinemic compared with the control group (p < 0.01). By analysis of variance no statistically significant difference in severity of coronary atherosclerosis on coronary angiograms was found. In conclusion, we demonstrated frequent disturbances in glucose metabolism indicating insulin resistance in patients with ischemic heart disease without a history of diabetes, but we could not demonstrate a relation between these disturbances and degree of coronary atherosclerosis.
American Journal of Cardiology | 1996
Lars Køber; Christian Torp-Pedersen; Michael Ottesen; Hans Burchardt; Eva Korup; Keld Lyngborg
The aim of this study was to assess the importance of congestive heart failure and left ventricular (LV) systolic dysfunction after an acute myocardial infarction (AIM) on long-term mortality in different age groups. A total of 7,001 consecutive enzyme-confirmed AMIs (6,676 patients) were screened for entry into the TRAndolapril Cardiac Evaluation (TRACE) study. Medical history, echocardiographic estimation of LV systolic function determined as wall motion index, infarct complications, and survival were documented for all patients. To study the importance of congestive heart failure and wall motion index independent of age, we performed Cox proportional-hazard models in 4 different age strata (< or = 55 years, 56 to 65 years, 66 to 75 years, and > 75 years). Patients in these strata had 1-year mortality rates of 5%, 11%, 21%, and 32%, respectively. Three-year mortality rates were 11%, 20%, 34%, and 55%, respectively. The risk ratios (and 95% confidence limits) associated with congestive heart failure in the same 4 age strata were 1.9 (1.3 to 2.9), 2.8 (2.1 to 3.7), 1.8 (1.5 to 2.2) and 1.8 (1.5 to 2.2), respectively. The risk ratios associated with decreasing wall motion index were 6.5 (3.6 to 11.4), 3.3 (2.3 to 4.6), 2.7 (2.2 to 3.4), and 2.1 (1.7 to 2.6), respectively. In absolute percentages, there was an excess 3-year mortality associated with congestive heart failure in the 4 age strata of 14%, 24%, 25%, and 28% respectively. The absolute excess in 3-year mortality associated with LV systolic dysfunction in the 4 age strata was 15%, 19%, 25%, and 21%, respectively. Thus, the relative importance of LV systolic dysfunction and congestive heart failure diminished with increasing age. However, the absolute excess mortality associated with congestive heart failure and LV systolic dysfunction was more pronounced in the elderly than in the young.
Echocardiography-a Journal of Cardiovascular Ultrasound and Allied Techniques | 2006
Gunnar H. Gislason; Niels Gadsbøll; Miguel A. Quinones; Lars Køber; Marie Seibæk; Hans Burchardt; Christian Torp-Pedersen
Objective: To study whether the use of echocardiographic left ventricular (LV) wall motion index (WMI) is a dependable parameter for identifying patients with LV dysfunction to be enrolled in multicenter trials. Methods: Videotaped echocardiographic examinations from 200 randomly selected patients that were screened for inclusion into the DIAMOND‐CHF and DIAMOND‐MI trials were reevaluated by an external expert echocardiographer. WMI was calculated using the 16‐segment LV model. Results: The external echocardiographer systematically found lower values of WMI than the core laboratory. The average difference in WMI was 0.18 (SD: 0.33) in the DIAMOND‐CHF trial and 0.09 (SD: 0.33) in the DIAMOND‐MI trial. The difference in WMI exceeded 0.33 in 34% of the patients in both trials. The cutoff value for inclusion into the DIAMOND trials was WMI ≤ 1.2. There was an agreement on WMI dichotomized to below or above 1.2 in 82% of the patients in both trials ( κ coefficient 0.66 for the DIAMOND‐CHF and 0.55 for the DIAMOND‐MI). Conclusions: Despite substantial interlaboratory variation in WMI in individual patients and a systematic lower WMI score by the external echocardiographer there was an acceptable overall agreement for identifying patients with severe impairment of LV function. This not only underscores the value of LV‐WMI as a useful tool for selecting high‐risk patients to be included in multicenter studies but also serves to warn against the use of rigid cutoff values for WMI in the treatment of individual patients.
Journal of the American College of Cardiology | 2004
Ida Gustafsson; Bente Brendorp; Marie Seibæk; Hans Burchardt; Per Hildebrandt; Lars Køber; Christian Torp-Pedersen
European Heart Journal | 2005
Finn Gustafsson; Charlotte Kragelund; Christian Torp-Pedersen; Marie Seibæk; Hans Burchardt; Dilek Akkan; Jens Jakob Thune; Lars Køber
European Heart Journal | 2004
Finn Gustafsson; Christian Torp-Pedersen; Hans Burchardt; Pernille Buch; Marie Seibæk; Erik Kjøller; Ida Gustafsson; Lars Køber
European Heart Journal | 2006
Ole Dyg Pedersen; Peter Søndergaard; Tonny Nielsen; Søren Junge Nielsen; Eric Steen Nielsen; Niels Falstie-Jensen; Ingolf Nielsen; Lars Køber; Hans Burchardt; Marie Seibæk; Christian Torp-Pedersen
European Heart Journal | 2004
Finn Gustafsson; Christian Torp-Pedersen; Marie Seibæk; Hans Burchardt; Lars Køber
Clinical Cardiology | 2003
Marie Seibæk; Henrik Vestergaard; Hans Burchardt; Carsten Sloth; Christian Torp-Pedersen; Steen Levin Nielsen; Per Hildebrandt; Oluf Pedersen